Zura Bio Ltd

Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company focused on immunology that came to market through a de-SPAC merger with JAWS Healthcare Innovators Acquisition Corp, a blank-check vehicle sponsored by Thiel Capital that completed its IPO in 2021. The company targets autoimmune and inflammatory diseases with a pipeline of antibody-based therapies and remains an active publicly traded entity in the biotechnology sector. Zura Bio filed an 8-K current report with the SEC on June 18, 2026, under accession number 0001104659-26-075826, representing its most recent regulatory disclosure. Sign up at SpacDesk for full filing history, deal analytics, and real-time alerts on Zura Bio and the broader SPAC universe.